4D Molecular Therapeutics, Inc. - Common Stock (FDMT)
5.3150
-0.6550 (-10.97%)
4D Molecular Therapeutics Inc is a biotechnology company focused on developing innovative gene therapies that leverage its proprietary platform technology
The company aims to create targeted and effective treatment options for a range of serious diseases by designing and delivering therapeutic genes directly to specific tissues, thereby enhancing the efficacy and safety of gene-based treatments. Through its commitment to advancing molecular medicine, 4D Molecular Therapeutics works to address unmet medical needs and improve patient outcomes by harnessing the power of the body's own biology.
4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to Regeneron's Eylea is set to begin in Q1 2025.
4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-free with 4D-150. The trial highlights safety and efficacy in reducing anti-VEGF treatments.
FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
4D Molecular Therapeutics' latest advancements in CF treatment. Get insights into their 4D-710 aerosolized genetic medicine for cystic fibrosis lung disease, including Phase 1/2 AEROW trial updates and Phase 3 clinical trial preparations.
Adverum Biotechnologies' Ixo-vec gene therapy for wet AMD. Preliminary LUNA Phase 2 trial data show safety, efficacy, and significant treatment burden reduction.
4D Molecular Therapeutics shares are trading lower by 12.7% Wednesday afternoon. The company announced pricing of an upsized underwritten public offering.
